Compare Mesoblast Limited (MESO) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Global X NASDAQ 100 Covered Call ETF trades at $17.81. The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | QYLD | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $20.96 | $18.52 |
52-Week Low | $12.88 | $16.46 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
QYLD trades at $17.66, down 0.84% with a bearish technical signal from moving averages. The ETF's covered-call strategy generates high income but has underperformed the Nasdaq-100's growth over the long term. Recent dividend payments of $0.18-$0.19 per share continue the fund's income-focused approach while technical indicators show neutral oscillators but bearish momentum signals.
The outlook remains challenging as QYLD's high yield comes at the cost of capital appreciation. While attractive for income-seeking investors, the fund faces structural headwinds in strong bull markets. Key risks include NAV erosion during market rallies and competition from lower-fee alternatives like GPIQ.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
